- Home
- DT vs BMRN Comparison
DT vs BMRN Comparison
Compare DT & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DT
- BMRN
- Stock Information
- Founded
- DT 2005
- BMRN 1996
- Country
- DT United States
- BMRN United States
- Employees
- DT N/A
- BMRN N/A
- Industry
- DT Computer Software: Prepackaged Software
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- DT Technology
- BMRN Health Care
- Exchange
- DT Nasdaq
- BMRN Nasdaq
- Market Cap
- DT 14.8B
- BMRN 13.7B
- IPO Year
- DT 2019
- BMRN 1999
- Fundamental
- Price
- DT $43.10
- BMRN $59.17
- Analyst Decision
- DT Buy
- BMRN Buy
- Analyst Count
- DT 26
- BMRN 22
- Target Price
- DT $60.29
- BMRN $94.00
- AVG Volume (30 Days)
- DT 3.2M
- BMRN 2.0M
- Earning Date
- DT 05-14-2025
- BMRN 05-01-2025
- Dividend Yield
- DT N/A
- BMRN N/A
- EPS Growth
- DT 143.79
- BMRN 153.71
- EPS
- DT 1.60
- BMRN 2.21
- Revenue
- DT $1,634,366,000.00
- BMRN $2,853,915,000.00
- Revenue This Year
- DT $21.56
- BMRN $12.23
- Revenue Next Year
- DT $15.07
- BMRN $9.93
- P/E Ratio
- DT $26.93
- BMRN $26.81
- Revenue Growth
- DT 19.81
- BMRN 17.97
- 52 Week Low
- DT $39.30
- BMRN $52.93
- 52 Week High
- DT $63.00
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- DT 35.61
- BMRN 37.64
- Support Level
- DT $42.53
- BMRN $52.93
- Resistance Level
- DT $44.18
- BMRN $60.93
- Average True Range (ATR)
- DT 2.06
- BMRN 3.18
- MACD
- DT 0.11
- BMRN -0.53
- Stochastic Oscillator
- DT 39.42
- BMRN 34.01
About DT Dynatrace Inc.
Dynatrace is a cloud-native company that focuses on analyzing machine data. Its product portfolio, delivered as software as a service, allows a client to monitor and analyze its entire IT infrastructure. Dynatrace's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to use it for a variety of applications throughout their businesses.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.